$2.22
-0.14 (-5.93%)
Open$2.36
Previous Close$2.36
Day High$2.36
Day Low$2.17
52W High$3.19
52W Low$1.46
Volume—
Avg Volume982.1K
Market Cap190.15M
P/E Ratio12.40
EPS$0.18
SectorBiotechnology
Analyst Ratings
Strong Buy
5 analysts
Price Target
+1,305.9% upside
Current
$2.22
$2.22
Target
$31.21
$31.21
$17.92
$31.21 avg
$31.70
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 55.52M | 53.66M | 361.03M |
| Net Income | -6,952,841 | -6,048,870 | 15.50M |
| Profit Margin | -12.5% | -11.9% | 4.3% |
| EBITDA | -4,249,418 | -3,902,317 | 29.24M |
| Free Cash Flow | — | — | 6.36M |
| Rev Growth | +3.5% | +3.5% | +17.6% |
| Debt/Equity | — | — | 0.65 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $258.92 | +3.43% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $425.28 | +1.41% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $143.44 | +3.25% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $528.19 | +2.45% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $810.24 | +0.53% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.61 | +1.79% | 37.6 | 30.39B |